Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 668

Sort by

Sort Order Select

Journal Articles

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Blood (2025) 145 (22): 2614–2629.

https://doi.org/10.1182/blood.2024024781

Published: 2025

Includes: Supplemental data

Journal Articles

N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation

Blood (2025) 145 (20): 2374–2389.

https://doi.org/10.1182/blood.2024025593

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Blood blood.2024027270.

https://doi.org/10.1182/blood.2024027270

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Blood (2024) 144 (Supplement 1): 2067.

https://doi.org/10.1182/blood-2024-201138

Published: 2024

Journal Articles

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Wei Tan, Minghao Dang, Upasana Ray, Luz Yurany Moreno Rueda, Maria Jose Acevedo-Calado, Hua Wang, Jun Wei, Li Qin, Isere Kuiatse, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 4640.

https://doi.org/10.1182/blood-2024-207917

Published: 2024

Journal Articles

An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Ling Qin, Yuping Zhong, Dongping Huang, Haitang Xie, Xin Du, Aijun Liao, Hongli Zhang, Shengli (Charles) Cai, Jin Lu

Blood (2024) 144 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2024-202871

Published: 2024

Journal Articles

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Blood (2024) 144 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2024-199797

Published: 2024

Journal Articles

Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial

Kai Fan, Qing Chen, Shehui Hu, Xin Zeng, Xiaolan Qin, Jing Sun

Blood (2024) 144 (Supplement 1): 1190.

https://doi.org/10.1182/blood-2024-202698

Published: 2024

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Xu Tan, Guo Chen, Yingying Ma, Maihong Wang, Qin Wen, Hong Liu, Xi Zhang, Cheng Zhang

Blood (2024) 144 (Supplement 1): 1449.

https://doi.org/10.1182/blood-2024-206572

Published: 2024

Journal Articles

Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment

Yanzhi Song, Erhui Yuan, Qishu Qin, Qi Wang, Zhanxiang Liu, Kong Gao, Zhihui Li, Yongqiang Zhao, Tong Wu

Blood (2024) 144 (Supplement 1): 2164.

https://doi.org/10.1182/blood-2024-202388

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Oren Pasvolsky, Mahmoud R. Gaballa, Melody R. Becnel, J Christine Ye, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2024-210080

Published: 2024

Journal Articles

Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 767.

https://doi.org/10.1182/blood-2024-204313

Published: 2024

Journal Articles

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Jingye Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2024-212110

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Wenzhuo Zhuang, Yuchen Zhang, Chunxiao Yang, Linlin Qin, Ruijing Hu, Menglu Chen, Xinyuan Zhang, Qi Li, Xingping Lang, Si Chen, Bingzong Li

Blood (2024) 144 (Supplement 1): 958.

https://doi.org/10.1182/blood-2024-198290

Published: 2024

Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2024-206453

Published: 2024

Journal Articles

Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Maria Velegraki, Cankun Wang, Deedra Nicolet, Krzysztof Mrózek, Payton Weltge, Ethan Hamp, Jill Buss, Andrea Laganson, Christopher C. Oakes, Jordan Krull, John C. Byrd, Richard M. Stone, Qin Ma, Ann-Kathrin Eisfeld, Zihai Li

Blood (2024) 144 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2024-211437

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only